内容紹介
A Case of Ascending Colon Cancer Showing Marked Reduction of Ascites by Bevacizumab Combination Chemotherapy
Summary
A 68-year-old woman presented to our hospital with abdominal fullness. Computed tomography(CT)revealed ascites and massive tumors in the abdominal cavity. She was diagnosed with ascending colon cancer with peritoneal dissemination and ovarian metastasis. After ileostomy, panitumumab plus mFOLFOX6 therapy was initiated, but it was discontinued due to adverse events. As the ascites rapidly increased, her chemotherapy was changed to bevacizumab(BV)plus FOLFIRI. BV combination therapy resulted in a dramatic decrease in ascites and improved her quality of life, whereas the therapy did not reduce the primary and metastatic lesions. Our case suggested that BV could decrease ascites by inhibiting vascular endothelial growth factor(VEGF)-induced vascular permeability.
要旨
症例は68歳,女性。腹部膨満を主訴に2010年7月に当院を受診した。腹部CTにて著明な腹水貯留と腹腔内の巨大腫瘍を認め,精査の結果,上行結腸癌による癌性腹膜炎・左卵巣転移と診断した。双孔式回腸人工肛門造設術を施行後,panitumumab+mFOLFOX6療法を施行したが,有害事象を認めたため中止となった。腹水の著明な増加のため,二次治療としてbevacizumab(BV)+FOLFIRI併用療法を施行した。BV併用療法後,原発巣および転移巣の縮小は認めないものの腹水の著明な減少を認め,quality of life(QOL)の改善が得られた。BVはvascular endothelial growth factor(VEGF)による血管透過性亢進を阻害することで,腹水減少に関与すると考えられた。
目次
Summary
A 68-year-old woman presented to our hospital with abdominal fullness. Computed tomography(CT)revealed ascites and massive tumors in the abdominal cavity. She was diagnosed with ascending colon cancer with peritoneal dissemination and ovarian metastasis. After ileostomy, panitumumab plus mFOLFOX6 therapy was initiated, but it was discontinued due to adverse events. As the ascites rapidly increased, her chemotherapy was changed to bevacizumab(BV)plus FOLFIRI. BV combination therapy resulted in a dramatic decrease in ascites and improved her quality of life, whereas the therapy did not reduce the primary and metastatic lesions. Our case suggested that BV could decrease ascites by inhibiting vascular endothelial growth factor(VEGF)-induced vascular permeability.
要旨
症例は68歳,女性。腹部膨満を主訴に2010年7月に当院を受診した。腹部CTにて著明な腹水貯留と腹腔内の巨大腫瘍を認め,精査の結果,上行結腸癌による癌性腹膜炎・左卵巣転移と診断した。双孔式回腸人工肛門造設術を施行後,panitumumab+mFOLFOX6療法を施行したが,有害事象を認めたため中止となった。腹水の著明な増加のため,二次治療としてbevacizumab(BV)+FOLFIRI併用療法を施行した。BV併用療法後,原発巣および転移巣の縮小は認めないものの腹水の著明な減少を認め,quality of life(QOL)の改善が得られた。BVはvascular endothelial growth factor(VEGF)による血管透過性亢進を阻害することで,腹水減少に関与すると考えられた。